HF
CRBP icon

Halpern Financial’s Corbus Pharmaceuticals CRBP Stock Holding History

Halpern Financial’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-33
Closed -$5.24K – 177
2020
Q1 		$5.24K Hold
33
– – ﹤0.01% 115
2019
Q4 		$5.46K Buy
+33
New +$4.88K ﹤0.01% 145

Other funds holding CRBP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Halpern Financial's CRBP Position: Q2 2020 in Review

Halpern Financial sold out of Corbus Pharmaceuticals (CRBP) in Q2 2020, closing a stake of 33 shares — an estimated $5.24K sold.

Halpern Financial first reported a position in CRBP in Q4 2019 and held it in 2 quarters. The position peaked at $5.46K in Q4 2019. 140 funds tracked by Wall St. Rank hold CRBP as of Q2 2020.

  • Halpern Financial reported no remaining Corbus Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Halpern Financial sold 33 Corbus Pharmaceuticals shares in Q2 2020, an estimated $5.24K.
  • Halpern Financial first reported a position in Corbus Pharmaceuticals in Q4 2019 and held it in 2 quarters.
  • Halpern Financial's Corbus Pharmaceuticals position peaked at $5.46K in Q4 2019.
  • 140 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2020.

Based on Halpern Financial's 13F filing for Q2 2020, filed 21 Sep 2023.